Artificial Embolization Device Downclassification To Be Discussed By Panel
This article was originally published in The Gray Sheet
Safety and effectiveness data on artificial embolization devices will be presented to FDA's Neurological Devices Panel at its June 12 meeting to provide input to the agency on the downclassification of the Class III preamendments devices. The meeting will be held at FDA's Corporate Building in Rockville, Maryland, beginning at 10:30 a.m.
You may also be interested in...
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”
After almost a year as CEO of Centrient, Rex Clements reflects on the company’s experiences operating amid a pandemic that has underlined the importance of a diversified supply chain, while also highlighting the firm’s sustainable manufacturing initiatives and calling for non-price criteria to be taken into account by procurement processes, in an exclusive interview with Generics Bulletin.